title: [Therapeutic choices in myeloma].
abstract: After having considered the elements which can rightly address to a precox diagnosis of the multiple myeloma, the AA. analyse the principal laboratory exams. Then, they refer about different therapeutic certificates underlining that the obtained results by the Prof. Reizenstein and Mathè teams are nearly corresponding. They discuss about the compositions and posologies of the most present therapeutic certificates underlining the importance of a precox diagnosis.
authors.forename: E
authors.initials: E
authors.lastname: Rapisarda
authors.forename: P
authors.initials: P
authors.lastname: Scarso
authors.forename: S
authors.initials: S
authors.lastname: Ferlito
authors.forename: R
authors.initials: R
authors.lastname: Rasa
authors.forename: F
authors.initials: F
authors.lastname: Tripi
mesh_terms: D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine
vernacular_title: La scelta terapeutica nel mieloma.